Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.65 |
| ▸ | ACE | P12821 | 5/20 | 0.65 |
| ▸ | CPA1 | P15085 | 2/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.65 |
| ▸ | TACR1 | P25103 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | IL2 | P60568 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607215 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29386502 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL8712438 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29413287 | 0.92 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL23178150 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL30712864 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL30712855 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL15342313 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29386041 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL22788735 | 0.87 | TACR1 (0.62) | MMEACECPA1ACE2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038902-A2 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2021-11-23 | — | — | US | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-5472978-A | Tachykinin antagonists for treating pain, migraine and antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 1995-12-05 | — | — | US | claimed |
| EP-0593559-A1 | AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LTD. (GB) | 1994-04-27 | — | — | EP | claimed |
| WO-1993001169-A2 | AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 1993-01-21 | — | — | WO | claimed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| CN-115792011-B | Separation detection method for N-acetyl protected amino acid and optical isomer thereof | 四川汇宇制药股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2025038902-A2 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-115541734-B | Method for measuring protected amino acid enantiomer by normal phase chromatography | 南京锐志生物医药有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | MME 896/4885ACE 140/4885CPA1 479/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | MME 1765/4885ACE 3407/4885CPA1 998/4885 |
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | CYP51A1, CYP17A1, CYP11A1 | MME 133/4885ACE 117/4885CPA1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.